Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders
DRP Guay - The American journal of geriatric pharmacotherapy, 2010 - Elsevier
Background: Few drugs are available for the management of hyperkinetic movement
disorders such as the dystonias, choreas, dyskinesias, and tics. Those that are available
(primarily neuroleptics) are associated with a wide range of potentially serious adverse
effects, including induction of tardive movement disorders. Tetrabenazine (TBZ) is a
monoamine-depleting agent initially studied in the 1950s and currently approved by the US
Food and Drug Administration for the treatment of chorea in Huntington's disease. Objective …
disorders such as the dystonias, choreas, dyskinesias, and tics. Those that are available
(primarily neuroleptics) are associated with a wide range of potentially serious adverse
effects, including induction of tardive movement disorders. Tetrabenazine (TBZ) is a
monoamine-depleting agent initially studied in the 1950s and currently approved by the US
Food and Drug Administration for the treatment of chorea in Huntington's disease. Objective …